Programme tenders, Hajj requirements and new adult vaccines drive a growing, cold-chain-dependent market. Sized from published research with a GCC and India lens, for buyers, suppliers and investors.
Programme tenders, Hajj requirements and new adult vaccines drive a growing, cold-chain-dependent market. Published estimates normalised to 2025 range from USD 396 m to USD 882 m; the Consulting Wallah central estimate is USD 750 m, growing at about 4% a year to USD 987 m by 2032. Scope differences between publishers explain most of the spread — the comparison table below states each one.
Growth is driven by mandatory meningococcal vaccination for Hajj/Umrah pilgrims and all 2026 Hajj workers (5-year validity) plus flu and COVID boosters; saudi pandemic-preparedness strategy: pre-pandemic stockpiles, advance purchase agreements and onshore production targeted for 2026; mass gatherings pipeline (Hajj, Expo 2030, FIFA World Cup 2034) raising demand for flu/meningococcal supply.
Context that matters for buyers and suppliers: Sanofi MoU with PIF-owned Lifera (contract manufacturer/new plant) and Arabio (distribution) to initially manufacture seven vaccines on Saudi mandatory immunisation schedule. Saudi Vaccine and Biomanufacturing Centre at KAUST Research & Technology Park: developed by RPDC (TAQNIA), KAUST and SaudiVax (agreement Mar 2018, groundbreaking Dec 2018), GE Healthcare FlexFactory single-use tech, Samsung Engineering turnkey; MERS-CoV focus. Saudi national vaccine procurement uses manufacturer-specific tender awards (2023). GCC vaccine volume ~62.2 mn doses in 2025; paediatric dominant, adult fastest-growing; Saudi ~57% of value.
The chart shows the Consulting Wallah central estimate: published figures normalised to 2025, median taken, and projected at the median published growth rate. The published range for 2025 is USD 396 m–USD 882 m; differences are mostly scope.
| Publisher (date) | Base value | Forecast | CAGR |
|---|---|---|---|
| Ken Research (2026-10) — Region: six GCC countries, human vaccines excl. passive anti | USD 882 mn (62.2 mn doses) (2025) | USD 1,145 mn (72.9 mn doses); 2031: USD 1,103 mn (2032) | 3.80% (2025-2032) |
| IMARC Group (2026-05) — Region: GCC vaccine market; Saudi Arabia largest share; conj | USD 396.5 mn (2025) | USD 566.2 mn (2034) | 3.92% (2026-2034) |
| IMARC Group (2026-01) — Region: MENA vaccine market (wider than GCC) | USD 2.4 bn (2025) | USD 3.9 bn (2034) | 5.64% (2026-2034) |
| Consulting Wallah central estimate | USD 750 m (2025) | USD 987 m (2032) | ~4% |
Source: Publisher pages as listed under Sources; CW estimate as described in Method.
Included: the therapeutic category as named, originator and generic/biosimilar, across hospital and retail channels. Excluded: adjacent classes, devices used for delivery. Price basis (list vs net) differs between publishers.
Shares as reported by the named sources; ranking is more reliable than the exact percentage.
| Segment | Share | Note | |
|---|---|---|---|
| Saudi Arabia | 57% | analytical estimate |
Source: Ken Research (2026-10)
| Segment | Share | Note | |
|---|---|---|---|
| Local vs international players | 70% | Ken Research ownership split |
Source: IMARC Group / Ken Research
| Axis | Segment | Figure | Note |
|---|---|---|---|
| By country (value) | UAE | 2nd | no share given |
| By country (value) | Kuwait, Qatar, Oman, Bahrain | 3rd-6th | in that order |
| By segment leaders (qualitative) | Paediatric vaccines | dominant | adult vaccines fastest growing |
| By segment leaders (qualitative) | Conjugate vaccines | leading technology | IMARC |
| By segment leaders (qualitative) | Hospital pharmacies / hospitals | leading channel / end user | IMARC |
| Volume | GCC doses 2024 | 60.8 mn | |
| Volume | GCC doses 2025 | 62.2 mn | |
| Volume | GCC doses 2032F | 72.9 mn |
Source: As listed under Sources.
| Country / region | Figure | Year | Source |
|---|---|---|---|
| GCC vaccine market | USD 882 mn | 2025 | Ken Research |
| GCC vaccine market | USD 396.5 mn | 2025 | IMARC Group |
| MENA vaccine market | USD 2.4 bn | 2025 | IMARC Group |
| Sanofi Gulf vaccine reach | >10 mn people/yr; >6 mn quadrivalent flu doses (2022) | 2022 | Fierce Pharma |
| Saudi influenza epidemic societal cost (estimate) | up to USD 1.33 bn | 2025 | BioSpectrum Asia (CSL Seqirus) |
Source: Sources as named; see Sources and method.
Consulting Wallah works this market from both sides: hospital groups in the UAE, Saudi Arabia, India and Bangladesh as buyers, and manufacturers in India, China, Singapore, Malaysia and the US as suppliers through the Network. Our observation is that registration status, in-country stock and structured quotations decide access in the GCC, while price and distributor reach decide it in India. CW observation
Opportunities we see: localisation via PIF Lifera + Sanofi + Arabio (seven mandatory-schedule vaccines) and CSL Seqirus + VIC cell-based flu at Sudair City (2026/27 season); saudi Vaccine and Biomanufacturing Centre (KAUST, SaudiVax, RPDC/TAQNIA) for MERS-CoV and epidemic vaccines; halal-certified vaccines for Middle East (SaudiVax).
| Date | Development | Source |
|---|---|---|
| 2026-05 | Saudi MoH mandates meningococcal vaccination for all 2026 Hajj season workers (dose >=10 days before duty, 5-year validity); flu and COVID boosters recommended | Gulf News |
| 2025-10 | CSL Seqirus, Vaccine Industrial Company and Saudi MoH sign MoU to localise cell-based seasonal and pandemic flu vaccine manufacturing at Sudair City; supply targeted for 2026/27 season | BioSpectrum Asia |
| 2025-10 | Saudi Arabia announced vaccine localisation partnerships with four multinational manufacturers (following 2024 local biomanufacturing strategy) | Ken Research |
| 2025 | Bahrain guidance makes meningococcal protection mandatory for residents travelling for pilgrimage (from age one), delivered via primary care centres | Ken Research |
| 2026-10 | Ken Research publishes GCC Vaccine Market Outlook to 2030/2032: USD 882 mn (2025) to USD 1,145 mn (2032) | Ken Research |
| 2026-05 | IMARC updates GCC Vaccine Market report: USD 396.5 mn (2025) to USD 566.2 mn (2034) | IMARC Group |
Source: Company and press announcements as named.
Key companies named across the sources; local distributors and implementation partners matter as much as the brand in the GCC and India.
Published estimates normalised to 2025 range from USD 396 m to USD 882 m. Consulting Wallah’s central estimate is USD 750 m in 2025, rising to about USD 987 m by 2032.
Published CAGRs range from 3.8% to 3.92%; our central case is about 4% a year to 2032.
Pfizer, Sanofi (Sanofi Pasteur), GSK, MSD (Merck & Co), Serum Institute of India, AstraZeneca, Moderna, BioNTech among others.
The summary on this page is free to read and share with attribution. The full report is free for hospital leaders and registered Consulting Wallah Network members, and priced on request for others.
The full report (PDF, 40 pages) adds the GCC and India deep-dives, hospital-level benchmarks from the Consulting Wallah Network and the full source tables. Free for hospital leaders and registered network members; otherwise priced on request.
How to read these figures. Published market-size estimates for this market vary widely because publishers define scope differently (software only vs software + services + logistics). Where we show a Consulting Wallah estimate we state the range of published figures it is triangulated from and our scope. Figures marked as reported are quoted from the named source. Nothing here is investment advice.